Zydus Lifesciences announced on Friday that it has partnered with the Lucknow-based CSIR-Central Drug Research Institute (CDRI) to create a treatment for osteoporosis resulting from chronic kidney disease. The two parties signed a collaborative research agreement to develop an oral medication by discovering small molecule inhibitors of Sclerostin, as stated by the Ahmedabad-based pharmaceutical company in a regulatory filing.
Comments
Post a Comment